Prenons le cas de ce bloc de poudingue, prélevé sous la Roche aux Corpias, à Tournavaux. Cette roche correspond à une coulée de boue qui a entraîné avec elle, des cailloux et des galets il y a 420 000 ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of each ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

Here's why La Roche-Posay is pulling its Effaclar Duo Acne Spot Treatment from retail shelves. La Roche-Posay is a brand under the L'Oreal Group umbrella. A La Roche-Posay spokesperson confirmed ...

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

The products are being recalled by the FDA for possible "benzene contamination." Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to ...

But those days had settled down. Or so we thought. This week, Roche made it feel like 2022 again. Just days before the AGBT meeting kicks off in Marco Island, FL, the company hosted a much ...

Proactiv Skin Smoothing Exfoliator and La Roche-Posay Effaclar Duo Dual Action Acne Treatment. The full list and lot numbers was posted online Tuesday. “Even with daily use of these products for ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Roivant, the source of Roche’s TL1A prospect, reported a 21% delta compared to placebo after 12 weeks. Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic ...